S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Avoro Capital Advisors/Q3 2025

Avoro Capital Advisors

Period: Q3 2025 Β· Filed: 2025-11-14
View on SEC EDGAR β†—
AUM
$7.74B
Total portfolio value
Positions
32
Reported securities
Top Holding
ASND
13.1% $1.02B
QoQ Changes
+4 / -3
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-11-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ASNDASCENDIS PHARMA$1.02B13.13%$198.81$274.50+38.1%
13.1%
UTHRUNITED THERAPEUTICS CORP$847.7M10.96%$419.21$555.91+32.6%
11.0%
MDGLMADRIGAL PHARMACEUTICALS INC$840.7M10.87%$458.66$528.10+15.1%
10.9%
ARGXARGENX SE$730.2M9.44%$737.56$939.68+27.4%
9.4%
KRYSKRYSTAL BIOTECH INC$490.4M6.34%$176.53$375.07+112.5%
6.3%
ARWRARROWHEAD PHARMACEUTICALS INC.$375.9M4.86%$34.49$83.99+143.5%
4.9%
KYMRKYMERA THERAPEUTICS INC$359.4M4.65%$56.60$113.51+100.5%
4.7%
MRUSMERUS N V$333.5M4.31%β€”β€”
4.3%
RNAMAVIDITY BIOSCIENCES INC$333.1M4.31%β€”β€”
4.3%
APLSAPELLIS PHARMACEUTICALS INC.$276.6M3.58%$22.63β€”
3.6%
CNTACENTESSA PHARMACEUTICALS PLC$262.1M3.39%$24.25$40.50+67.0%
3.4%
QUREUNIQURE NV$259.4M3.35%$58.37$41.81-28.4%
3.4%
XENEXENON PHARMACEUTICALS INC$216.8M2.80%$40.15$60.96+51.8%
2.8%
AKROAKERO THERAPEUTICS INC$187.8M2.43%β€”β€”
2.4%
VERAVERA THERAPEUTICS INC$180.5M2.33%$29.06$41.20+41.8%
2.3%
SLNOSOLENO THERAPEUTICS INC$174.3M2.25%$67.60β€”
2.3%
GPCRSTRUCTURE THERAPEUTICS INC.$144.4M1.87%$28.00$53.45+90.9%
1.9%
TRMLTOURMALINE BIO INC$122.2M1.58%β€”β€”
1.6%
OCULOCULAR THERAPEUTIX INC$119.8M1.55%$11.69$9.64-17.5%
1.6%
FOLDAMICUS THERAPEUTICS INC.$118.4M1.53%β€”β€”
1.5%
ETNB89BIO INC$93.9M1.21%β€”β€”
1.2%
TSHATAYSHA GENE THERAPIES INC$71.0M0.92%$3.27$6.53+99.7%
0.9%
ALKSALKERMES PLC$67.2M0.87%$30.00$54.58+81.9%
0.9%
ORKAORUKA THERAPEUTICS INC$25.6M0.33%$19.23$85.21+343.1%
0.3%
SEPNSEPTERNA INC$25.2M0.33%$18.81$34.00+80.8%
0.3%
MNKDMANNKIND CORP$24.0M0.31%$5.37$4.52-15.8%
0.3%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$14.3M0.19%$7.17$18.95+164.3%
0.2%
BCRXBIOCRYST PHARMACEUTICALS INC$9.5M0.12%$7.59$9.84+29.6%
0.1%
WHWKWHITEHAWK THERAPEUTICS INC$5.4M0.07%$1.90$4.19+120.5%
0.1%
TNGXTANGO THERAPEUTICS INC$4.6M0.06%$8.40$29.46+250.7%
0.1%

Quarter-on-Quarter Activity

Q3 2025 vs. Q2 2025

New Positions (4)

TickerIssuerNotionalSince Filing
GPCRCALLSTRUCTURE THERAPEUTICS INC.$144.4M+90.9%
ORKAORUKA THERAPEUTICS INC$25.6M+343.1%
TNGXTANGO THERAPEUTICS INC$4.6M+250.7%
GPCRCALLSTRUCTURE THERAPEUTICS INC.$2.2M+90.9%

Exited Positions (3)

TickerIssuerNotional
BPMCBLUEPRINT MEDICINES CORP$48.1M
GLUEMONTE ROSA THERAPEUTICS INC$16.8M
RAREULTRAGENYX PHARMACEUTICAL INC$12.0M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
CNTACENTESSA PHARMACEUTICALS PLC$196.4M+116.2%+67.0%
OCULOCULAR THERAPEUTIX INC$51.1M+38.5%-17.5%
SLNOSOLENO THERAPEUTICS INC$2.5M+25.7%
QUREUNIQURE NV$208.9M+22.6%-28.4%
AKROAKERO THERAPEUTICS INC$1.1M+13.0%
MRUSMERUS N V$167.5M+12.3%
RNAMAVIDITY BIOSCIENCES INC$132.9M+8.4%
SEPNSEPTERNA INC$12.1M+8.1%+80.8%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
UTHRCALLUNITED THERAPEUTICS CORP$-676.6M-91.6%+32.6%
BCRXBIOCRYST PHARMACEUTICALS INC$-30.8M-72.2%+29.6%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$-181.5M-51.8%+164.3%
MNKDMANNKIND CORP$2.1M-23.6%-15.8%
ALKSALKERMES PLC$-15.8M-22.8%+81.9%
FOLDAMICUS THERAPEUTICS INC.$15.3M-16.5%
ARGXARGENX SE$82.5M-15.7%+27.4%
UTHRCALLUNITED THERAPEUTICS CORP$166.7M-14.7%+32.6%
← Back to Hedge Funds